Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:CRBP NASDAQ:OGI NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.50+0.1%$21.21$8.61▼$23.50$151.73M0.51292,579 shs270,257 shsCRBPCorbus Pharmaceuticals$8.32+1.6%$9.66$6.72▼$20.56$151.74M2.57735,268 shs335,420 shsOGIOrganigram Global$1.03-2.8%$1.26$1.02▼$2.24$149.21M1.43473,316 shs1.07 million shsZYBTZhengye Biotechnology$0.81-3.0%$0.92$0.68▼$13.08$39.34M-2.4178,750 shs72,173 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+0.09%+0.30%+0.77%+88.00%+147.93%CRBPCorbus Pharmaceuticals+1.59%+10.05%-24.57%-13.60%-5.78%OGIOrganigram Global-2.83%-3.74%-3.74%-27.97%-26.43%ZYBTZhengye Biotechnology-3.04%-6.40%-15.47%+11.81%-87.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.50+0.1%$21.21$8.61▼$23.50$151.73M0.51292,579 shs270,257 shsCRBPCorbus Pharmaceuticals$8.32+1.6%$9.66$6.72▼$20.56$151.74M2.57735,268 shs335,420 shsOGIOrganigram Global$1.03-2.8%$1.26$1.02▼$2.24$149.21M1.43473,316 shs1.07 million shsZYBTZhengye Biotechnology$0.81-3.0%$0.92$0.68▼$13.08$39.34M-2.4178,750 shs72,173 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+0.09%+0.30%+0.77%+88.00%+147.93%CRBPCorbus Pharmaceuticals+1.59%+10.05%-24.57%-13.60%-5.78%OGIOrganigram Global-2.83%-3.74%-3.74%-27.97%-26.43%ZYBTZhengye Biotechnology-3.04%-6.40%-15.47%+11.81%-87.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 1.80Reduce$22.65-3.62% DownsideCRBPCorbus Pharmaceuticals 2.75Moderate Buy$42.00404.81% UpsideOGIOrganigram Global 2.33HoldN/AN/AZYBTZhengye Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ZYBT, OGI, ASRT, and CRBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/9/2026OGIOrganigram Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/29/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/27/2026CRBPCorbus Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $30.005/26/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026CRBPCorbus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/22/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $44.005/15/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/13/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$21.80 ➝ $23.505/13/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $54.005/13/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$118.71M1.28$0.02 per share1,436.06$14.63 per share1.61CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/AOGIOrganigram Global$185.07M0.78N/AN/A$1.86 per share0.55ZYBTZhengye Biotechnology$16.64M2.29N/AN/A$0.93 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$30.38M-$5.69N/A21.17N/A-34.94%-38.72%-13.32%7/30/2026 (Estimated)CRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)OGIOrganigram Global-$17.70M-$0.13N/A25.75N/A-9.22%-13.41%-9.09%8/12/2026 (Estimated)ZYBTZhengye Biotechnology-$9.98MN/AN/AN/AN/AN/AN/AN/AN/ALatest ZYBT, OGI, ASRT, and CRBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/12/2026Q2 2026OGIOrganigram Global-$0.01-$0.01N/A-$0.01$50.56 million$42.99 million5/8/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million4/28/2026Q4 2025ZYBTZhengye BiotechnologyN/A-$0.0750N/A-$0.0750N/A$3.97 million3/16/2026Q4 2025ASRTAssertio-$3.05-$1.86+$1.19-$1.86$6.20 million$13.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.521.821.57CRBPCorbus PharmaceuticalsN/A7.927.92OGIOrganigram GlobalN/A2.821.30ZYBTZhengye Biotechnology0.031.140.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CRBPCorbus Pharmaceuticals64.64%OGIOrganigram Global34.63%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipASRTAssertio5.70%CRBPCorbus Pharmaceuticals3.50%OGIOrganigram Global0.09%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio206.46 million6.09 millionOptionableCRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableOGIOrganigram Global1,139140.77 million140.64 millionOptionableZYBTZhengye Biotechnology27847.39 millionN/AN/AZYBT, OGI, ASRT, and CRBP HeadlinesRecent News About These CompaniesZhengye Biotechnology (NASDAQ:ZYBT) Stock Price Up 3.1% - Time to Buy?June 10, 2026 | americanbankingnews.comZhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 NoticeJune 4, 2026 | tipranks.comZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJune 4, 2026 | globenewswire.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial ResultsApril 28, 2026 | prnewswire.comZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026April 6, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share StructureApril 6, 2026 | globenewswire.comZhengye Biotechnology Holding Ltd ZYBTMarch 28, 2026 | morningstar.comMZhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGMMarch 25, 2026 | tipranks.comZhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGMFebruary 23, 2026 | tipranks.comZhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to ShareholdersFebruary 11, 2026 | markets.businessinsider.comZhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder LetterFebruary 10, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to ShareholdersFebruary 10, 2026 | globenewswire.comWhy Zhengye Biotechnology Holding Limited’s (ZYBT) Stock Is Up 5.27%January 11, 2026 | aaii.comAIs Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 3.8% Concerning?September 14, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd trading resumesAugust 22, 2025 | msn.comZhengye Biotechnology Holding Ltd trading halted, volatility trading pauseAugust 21, 2025 | msn.comZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Robinhood, SoFi, and Webull Are Telling Very Different StoriesBy Peter Frank | May 17, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 2026AI Server Earnings: Wall Street Sees One Clear StandoutBy Leo Miller | June 5, 2026ZYBT, OGI, ASRT, and CRBP Company DescriptionsAssertio NASDAQ:ASRT$23.50 +0.02 (+0.09%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$23.49 -0.01 (-0.04%) As of 06/15/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Corbus Pharmaceuticals NASDAQ:CRBP$8.32 +0.13 (+1.59%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$8.19 -0.13 (-1.51%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Organigram Global NASDAQ:OGI$1.03 -0.03 (-2.83%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Zhengye Biotechnology NASDAQ:ZYBT$0.80 -0.03 (-3.04%) Closing price 06/15/2026 03:55 PM EasternExtended Trading$0.83 +0.03 (+3.60%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
